Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing proprietary therapies for central nervous system disorders. Its key products include roluperidone for negative symptoms in schizophrenia, and in-licensed compounds like MIN-301 for Parkinson’s disease and seltorexant for insomnia and depression. The company targets high unmet medical needs globally, leveraging innovative mechanisms, clinical data, and strategic collaborations to advance novel CNS treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.